opioid-induced constipation
Pain · 2009–2009
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| methylnaltrexone bromide Treatment of opioid-induced constipation in palliative care patients who have failed to respond to, or are unable to tolerate, laxative therapies. | Jul 2009 | Recommended with restriction | no section in document |
| methylnaltrexone bromide Initial and continuing treatment of opioid-induced constipation in palliative care patients who have failed to respond to, or are unable to tolerate, laxative… | Mar 2009 | Not recommended | no section in document |
Appraised elsewhere
NICE, in England and Wales, has appraised 3 technologies for this condition, recommending 2 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| naldemedineNaldemedine for treating opioid-induced constipation | TA651 | recommended | 2020-09 |
| methylnaltrexone bromideMethylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal) | TA468 | terminated | 2017-08 |
| naloxegolNaloxegol for treating opioid‑induced constipation | TA345 | recommended | 2015-07 |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| naloxegol + purified waterMOVANTIK naloxegol (as oxalate) 12.5 mg film-coated tablet blister pac | 2016 | 2 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.